Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-619 in relapsed/refractory multiple myeloma
NCT06381141Phase 1Active, not recruiting
- Sponsor
- Cullinan Therapeutics
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cln-619 in multiple myeloma (MM), sponsored by Cullinan Therapeutics. Primary endpoints: Adverse Events, Serious Adverse Events and 8 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
cln-619
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06381141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06381141.